Aptose Biosciences (APTO) announced that the Cohort Safety Review Committee – CSRC – monitoring Aptose’s Phase 1/2 TUSCANY trial of tuspetinib ...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback